<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">A rolling IND submission enables the fastest clinical start if non-clinical data, product stability or characterization data would hold up the IND filing. Early contacts between the sponsor and regulatory authorities would enable the development of a strategy for joint review, discussion of risk mitigation options and approval of clinical development plans. Recently issued guidance from the US Food and Drug Administration on Emergency Use Authorization also opens opportunities that may permit the agency to waive otherwise applicable cGMP requirements
 <sup>
  <xref ref-type="bibr" rid="CR22">22</xref>
 </sup>.
</p>
